The pharmacokinetics of topotecan and its carboxylate form following separate intravenous administration to the dog

Pharmaceutical Research

Volumn 14, Issue 10, 1997, Pages 1461-1465

  Davies, Brian E ^a,c   Minthorn, Elisabeth A ^a   Dennis, Michael J ^a   Rosing, Hilde ^b   Beijnen, Jos H ^b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b UTRECHT UNIVERSITY   (Netherlands)

^c Bracco Diagnostics ^*  (United States)

Author keywords

Pharmacokinetics; Reversible metabolism; Topoisomerase I inhibitor; Topotecan

Indexed keywords

DNA TOPOISOMERASE; DRUG METABOLITE; SKF 105992; TOPOTECAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOAVAILABILITY; BLOOD LEVEL; CONTROLLED STUDY; DOG; DRUG CLEARANCE; DRUG METABOLISM; INTRAVENOUS ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; NONHUMAN; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; BIOTRANSFORMATION; DNA TOPOISOMERASES, TYPE I; DOGS; ENZYME INHIBITORS; FEMALE; INJECTIONS, INTRAVENOUS; TOPOTECAN;

EID: 0030728122     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1012189225880     Document Type: Article

References (14)

1. L. F. Liu. Annu. Rev. Biochem. 58:351-375 (1989).
2. W. J. M. Underberg, R. M. J. Goossen, B. R. Smith, and J. H. Beijnen. J. Pharm. Biomed. Anal. 8:681-683 (1990).
3. L. B. Grochow, E. K. Rowinsky, R. Johnson, S. Ludeman, S. H. Kaufmann, F. L. McCabe, B. R. Smith, L. Hurowitz, A. DeLisa, R. C. Donehower, and D. A. Noe. Drug. Metab. Dispos. 20:706-713 (1992).
4. R. K. Johnson, F. L. McCabe, L. F. Faucette, R. P. Hertzberg, W. D. Kinsbury, J. C. Boehm, M. J. Caranfa, and K. G. Proc. AACR 30:623 (1989).
5. H. Rosing, E. Doyle, B. E. Davies, and J. H. Beijnen. J. Chromatography B. 668:107-115 (1995).
6. G. D. Allen. Biopharm. Drug Dispos. 11:477-498 (1990).
7. H. Cheng and W. J. Jusko. In D. Argenio (ed.) Advanced Methods of Pharmacokinetic and Pharmacodynamic Systems Analysis, Plenum Press, NY, 1991, pp. 13-20.
8. H. Cheng and W. J. Jusko. Pharm. Res. 7:1003-1010 (1990).
9. H. Cheng, and W. J. Jusko. Biopharm. Drug Dispos. 14:721-766 (1993).
10. I. Walter-Sack, J. X. de Vries, C. Kreiner, A. Ittensohn, G. Stenzhorn, A. Voss, and E. Weber. Clin. Investig. 71:240-246 (1993).
11. M.-L. Chen and A. J. Jackson. Pharm. Res. 8:25-32 (1991).
12. D. O. Scott, D. S. Bindra, S. C. Sutton, and V. J. Stella. Drug Metab. Dispos. 22:438-442 (1994).
13. D. O. Scott, D. S. Bindra, and V. J. Stella. Pharm. Res. 10:1451-1457 (1993).
14. F. M. Muggia, P. J. Creaven, H. H. Hansen, M. H. Cohen, and O. S. Selawry. Cancer Chemother. Rep. 56:515-521 (1972).